Vitamin D as an Early Predictor of Multiple Sclerosis Activity and ProgressionAlberto Ascherio, Christoph Pohl, Kassandra L. Munger et al.|JAMA Neurology|2014Cited by 514
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Rupert Sandbrink, Mark S. Freedman et al.|The Lancet|2007Cited by 502
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MSG. Francis, Michel Chofflon, Richard AC Hughes et al.|DIAL (Catholic University of Leuven)|2001Cited by 472
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Christoph Pohl, Mark S. Freedman et al.|The Lancet Neurology|2009Cited by 370
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and ProgressionMarianna Cortese, Tuula Pirttilä, Ludwig Kappos et al.|Neurology|2025Cited by 3